Global Cord Blood Corporation (CO) |
| 2.9876 0 (0%) 06-09 09:43 |
| Open: | 2.21 |
| High: | 3.32 |
| Low: | 2.22 |
| Volume: | 0 |
| Market Cap: | 400(M) |
| PE Ratio: | 5.06 |
| Exchange: | New York Stock Exchange |
| Industry: | Medical - Diagnostics & Research |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 159.03 |
| Resistance 1: | 146.09 |
| Pivot price: | 141.26 |
| Support 1: | 125.16 |
| Support 2: | 104.13 |
| 52w High: | 3.59 |
| 52w Low: | 0.6001 |
Global Cord Blood Corporation (GCBC), alongside its associated entities, provides specialized services related to umbilical cord blood within the People's Republic of China. The company's operations involve the testing, processing, and long-term storage of cord blood for both private subscribers and donated samples. For the latter, it also facilitates donor matching. As of March 31, 2022, GCBC managed three cord blood banks situated in key regions: Beijing municipality, Guangdong province, and Zhejiang province. The company, which is headquartered in Central, Hong Kong, rebranded as Global Cord Blood Corporation in March 2018, having previously been known as China Cord Blood Corporation. Currently, it functions as a subsidiary under Blue Ocean Structure Investment Company Ltd.
| EPS | -4.740 |
| Book Value | 45.270 |
| PEG Ratio | 1.51 |
| Gross Profit | 33.155 |
| Profit Margin (%) | -5.43 |
| Operating Margin (%) | 7.33 |
| Return on Assets (ttm) | 6.2 |
| Return on Equity (ttm) | -9.4 |
Sun, 26 Jul 2026
Global Cord Blood Corporation Revenue Breakdown – OTC:CORBF - TradingView
Thu, 18 Jun 2026
Cord Blood Industry Consolidation Escalates in 2026 - BioInformant
Wed, 17 Jun 2026
Changing Dynamics in Umbilical Cord Blood and Tissue Banking in 2026 - BioInformant
Mon, 01 Jun 2026
Pivotal Trends Impacting the Global Cord Blood and Tissue Industry in 2026 - BioInformant
Thu, 23 Apr 2026
GMRS Stock Price and Chart — NYSE:GMRS - TradingView
Wed, 15 Apr 2026
Stem Cell Umbilical Cord Blood Market Size to Hit USD 30.16 Billion by 2035 - Precedence Research
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |